U.S. patent application number 17/058887 was filed with the patent office on 2021-07-08 for targeting anabolic drugs for accelerated fracture repair.
The applicant listed for this patent is Purdue Research Foundation. Invention is credited to Philip Stewart Low, Stewart A. Low, Jeffery Jay Howard Nielsen, Mingding Wang.
Application Number | 20210206820 17/058887 |
Document ID | / |
Family ID | 1000005493790 |
Filed Date | 2021-07-08 |
United States Patent
Application |
20210206820 |
Kind Code |
A1 |
Low; Philip Stewart ; et
al. |
July 8, 2021 |
TARGETING ANABOLIC DRUGS FOR ACCELERATED FRACTURE REPAIR
Abstract
Aspects of the disclosure include material and methods for the
targeted delivery of growth factors, vasoactive peptides and other
representative anabolic peptide drugs from different signaling
cascades to bone fracture for accelerated healing is disclosed
herein. Aspects of the disclosure can be used to treat bone
fractures and bone defects.
Inventors: |
Low; Philip Stewart; (West
Lafayette, IN) ; Low; Stewart A.; (West Lafayette,
IN) ; Nielsen; Jeffery Jay Howard; (West Lafayette,
IN) ; Wang; Mingding; (San Jose, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Purdue Research Foundation |
West Lafayette |
IN |
US |
|
|
Family ID: |
1000005493790 |
Appl. No.: |
17/058887 |
Filed: |
May 30, 2019 |
PCT Filed: |
May 30, 2019 |
PCT NO: |
PCT/US2019/034764 |
371 Date: |
November 25, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62678016 |
May 30, 2018 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 47/645 20170801;
C07K 14/51 20130101; C07K 14/78 20130101; C07K 2319/02 20130101;
A61K 38/00 20130101 |
International
Class: |
C07K 14/51 20060101
C07K014/51; A61K 47/64 20060101 A61K047/64; C07K 14/78 20060101
C07K014/78 |
Claims
1-18. (canceled)
19. A compound having a structure of: X-Y-Z wherein: X is a Src
kinase inhibitor; Y is absent or a linker; and Z is a
bone-targeting molecule, or a pharmaceutically acceptable salt
thereof.
20. The compound of claim 19, wherein Z comprises a
polypeptide.
21. The compound of claim 19, wherein Z comprises not less than 4
and not more than 40 amino acid residues.
22. The compound of claim 21, wherein at least one amino acid is
aspartic acid or glutamic acid.
23. The compound of claim 19, wherein Z comprises not less than 6
and not more than 20 glutamic acid residues.
24. The compound of claim 23, wherein Z is 10 D-glutamic acid
residues.
25. The compound of claim 19, wherein Z comprises not less than 6
and not more than 20 aspartic acid residues.
26. The compound of claim 25, wherein Z is 10 D-aspartic acid
residues.
27. The compound of claim 19, wherein Y is a releasable linker or
non-releasable linker.
28. The compound of claim 27, wherein the releasable linker
comprises at least one releasable linker group, each releasable
linker group being independently selected from the group consisting
of a disulfide (S-S), an ester, and a protease specific amide
bond.
29. The compound of claim 27, wherein the non-releasable linker
comprises at least one non-releasable linker group, each
non-releasable linker group being independently selected from the
group consisting of a carbon-carbon bond, ether, and an amide.
30. The compound of claim 27, wherein Y comprises one or more
ethylene glycol unit.
31. The compound of claim 30, wherein Y comprises 2-8 oxyethylene
units.
32. The compound of claim 19, wherein the Src inhibitor is selected
from the group consisting of Dasatinib and E739.
33. A compound having a structure of: X-Y-Z wherein: X is an agent
that activates sphingosine-1-phosphate (S1P); Y is absent or a
linker; and Z is a bone-targeting molecule, or a pharmaceutically
acceptable salt thereof.
34. The compound of claim 33, wherein the S1P is selected from the
group consisting of a Sphingosine-1-phosphate receptor 1 (S1P1R)
agonist and a S1P lyase inhibitor.
35. The compound of claim 34, wherein the SIP1R agonist is
Ozanimod.
36. The compound of claim 34, wherein the S1P lyase inhibitor is
4-deoxypyridoxine (DOP).
37. A compound having a structure of: X-Y-Z wherein: X is a
neuropeptide; Y is absent or a linker; and Z is a bone-targeting
molecule, or a pharmaceutically acceptable salt thereof.
38. The compound of claim 37, wherein the neuropeptide is selected
from the group consisting of Substance P, vasoactive intestinal
peptide (VIP), pituitary adenylate cyclase-activating polypeptide
(PACAP), amylin, and calcitronin gene-like related peptide (CGRP).
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent
Application No. 62/678,016, filed on May 30, 2018. This application
is incorporated herein by reference in its entirety for all
purposes.
FIELD OF THE INVENTION
[0002] Aspects of the present disclosure relate to the materials
and methods for treating bone fractures and bone defects.
BACKGROUND
[0003] Src tyrosine kinase plays a crucial role in bone metabolism:
despite its ubiquitous expression profile, the only apparent
phenotypical abnormality in a Sarcoma-knockout (Src-KO) mouse
strain was osteopetrosis. Although Src inhibitors inhibit both the
formation and activity of osteoblasts (OBs) in vitro, the number of
osteoclasts (OCs) derived from Src-KO mice were actually elevated
in Src-KO mice, measuring more than twice that in wild-type (WT)
mice. Also, a marked increase in both osteoblast number and
activity was observed in vivo in Src-KO mice. These results confirm
that the osteopetrosis phenotype of Src-KO mice was not a result of
reduced osteoclast formation, but rather of boosted osteoblast
activity as well as reduced osteoclast function. Moreover,
osteoblasts derived from Src-KO mice demonstrated unremarkable
morphological features compared to those harvested from WT mice,
and were able to fully regulate normal osteoclast differentiation
via the receptor activator of nuclear factor kappa-B
ligand/receptor activator of nuclear factor kappa-B/osteoprotegerin
(RANKL/RANK/OPG) pathway. Thus, this bone-resorption defect should
be easily alleviated by restoring normal Src functionality in
osteoclasts, reducing potential risks on the musculoskeletal system
involved in long-term use of Src inhibitors for fracture
healing.
[0004] Broadly, peptide anabolic drugs include different categories
of protein or the fragments thereof. They are represented by bone
morphogenetic protein pathway signaling peptides including P4, bone
forming peptide (BFP) and peptide from bone morphogenetic protein 9
(pBMP9); insulin-like growth factor (IGF) derived peptides
including mechano growth factor (MGF) and Preptin; bone stimulatory
neuropeptides including Substance P and vasoactive intestinal
protein (VIP); and peptides enhancing vascular functions, including
C-type Natriuretic peptide (CNP), targeted prothrombin peptide
(TP508) and VIP. Each of these peptides may have its own unique
mechanism working to regulate bone growth, as will be outlined in
the detailed description.
[0005] Current clinical treatment of fractures generally does not
include the use of site-specific anabolic drugs. In fact, the only
drugs approved for clinical use on such fractures are bone
morphogenic protein (BMP)-2 (approved for use only in tibial
trauma) and BMP-7 (discontinued), which are applied locally and
generally used in the treatment of open long bone fractures and
spinal fusions. The need for broader application of anabolic drugs
to treat bone maladies such as osteoporotic fractures with efficacy
is evident.
[0006] Therefore, it is desirable to have a fracture treatment drug
that is administered systemically yet targets the fracture site
with evident efficacy.
SUMMARY
[0007] A first aspect of the present disclosure includes at least
one compound of the formula X-Y-Z, or a pharmaceutically acceptable
salt thereof, or a metabolite thereof, wherein X is at least one
agent that improves bone density, mechanical strength, bone
deposition, or quality; Z is at least one bone-targeting molecule;
and Y is a linker that joins and/or links X and Z. In some aspects,
X is at least one agent that enhances the activity or one agent
that improves bone density, mechanical strength, bone deposition or
other agent that promotes bone healing and/or growth. Consistent
with some of these aspects, Z is at least one negatively charged
oligopeptide or an equivalent thereof that binds to hydroxyapatite
and/or raw bone.
[0008] The second aspect includes the compound according to the
first aspect, wherein when X is a polypeptide, any polypeptide
having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%,
89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, and/or 100%
identity to X can be used to practice the invention.
[0009] In some aspects, Y is at least one polypeptide comprising at
least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, and/or 100% sequence
identity to amino acid residues 35-40, 35-41, 35-42, 35-43, 35-44,
35-45, 35-46, 35-47, 35-48, 35-49, 35-50, 35-51, 35-52, 35-55,
35-84, 41-44, 41-45, 41-46, 41-47, 41-48, 41-49, 41-50, and/or
41-84 of a full length parathyroid hormone related peptide or
parathyroid hormone, and/or at least one Cathepsin K sensitive
polypeptide.
[0010] In some aspects, Z is at least one polypeptide comprising
about 4 or more, from about 4 to about 100, from about 4 to about
50, from 4 to about 20, from about 4 to about 15, from about 4 to
about 10 acidic amino acid residues, polyphosphate,
2-aminohexanedioic (aminoadipic) acid or derivatives thereof,
and/or alendronate or derivatives thereof. In some aspects, Z is at
least one polypeptide comprising about 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, and/or 30 acidic amino acid residues, polyphosphate,
2-aminohexanedioic acid or derivatives thereof, and/or alendronate
or derivatives thereof. In other aspects, Z is at least one
negatively charged oligopeptide or an equivalent thereof that binds
to hydroxyapatite and/or raw bone.
[0011] The targeted delivery strategy recited in some aspects of
the present disclosure enable the delivery of Src inhibitors
specifically to bone fracture surfaces thereby facilitating
fracture healing. This in vivo efficacy is shown by the
acceleration of fracture healing observed using the Src inhibitors
Dasatinib and E738.
[0012] In addition to Src inhibitors, a group of peptides targeted
specifically to the fracture surfaces also demonstrates an enhanced
ability to facilitate fracture healing. These peptides include
osteopontin derived fragments such as osteopontin-derived peptide
(ODP), collagen binding motif (CBM); BMP fragments such as P4, BFP,
pBMP7; IGF fragments such as MGF and Preptin; neuropeptides such as
Substance P and VIP; vasoconstrictive fragments such as CNP, TP508
and VIP; and other anabolic drugs such as osteogenic growth peptide
(OGP). The in vivo efficacy of these peptides for accelerated
fracture healing are demonstrated herein. All peptide conjugates
are produced by solid phase synthesis.
[0013] Some aspects of this disclosure include compounds
comprising: a compound of the formula X-Y-Z, wherein X is at least
one agent that modulates bone growth such as activity of Src
tyrosine kinase; Z is at least one bone-targeting molecule; and Y
is a linker that joins and/or links X and Z; or a pharmaceutically
acceptable salt thereof, or a metabolite thereof. In some aspects,
Z is at least one polypeptide comprising 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19 and/or 20 acidic amino acid residues. In
some aspects, X is selected from the group consisting of Dasatinib
and E738. In some aspects, Y is a releasable linker selected from
disulfide; ester; or protease specific amide bond. In some aspects,
Y is a nonreleasable bond selected from carbon-carbon bond; or
amide bond.
[0014] In some aspects, this disclosure includes a compound of the
formula X-Y-Z, wherein X is at least one peptide or a fragment
thereof that modulates activity of bone and cartilage formation; Z
is at least one bone-targeting molecule; and Y is a linker that
joins and/or links X and Z; or a pharmaceutically acceptable salt
thereof, or a metabolite thereof. In some aspects, Y is a
releasable linker selected from disulfide; ester; or protease
specific amide bond. In some aspects, Y is a nonreleasable bond
selected from carbon-carbon bond; or amide bond. In some aspects, Y
is a peptide belonging to the natural sequence of Z. In some
aspects, Y is a (polyethylene glycol) PEG linker. In some aspects Y
is a PEG linker comprised of 2-8 oxyethylene units. In some
aspects, Z comprises at least 10 aspartic or glutamic acids
conjugated to X. In some aspects, Z comprises at least 20 aspartic
or glutamic acids conjugated to X. In some aspects, the compound
may be produced by solid phase synthesis.
[0015] In some aspects, X is a bone anabolic peptide derived from
BMP. In some aspects, X is a bone anabolic peptide derived from
IGF. In some aspects, X is a bone anabolic peptide derived from a
neuropeptide. In some aspects, X is a bone anabolic peptide that
improves vascular function and/or vascularization. In some aspects,
X is OGP. In some aspects, the peptide is BFP, P4, or pBMP9. In
some aspects, the peptide is MGF or preptin. In some aspects, the
peptide is Substance P or VIP. In some aspects, the peptide is
TP508, VIP, or CNP. Unless indicated otherwise, the invention may
be practiced by combining any X with any Z and optionally any
suitable linking group Y. [0016] 1. A compound comprising: [0017] a
compound of the formula X-Y-Z, wherein [0018] X is at least one
agent that modulates activity selected from the group consisting
of: Src Inhibitors, Sphingosine1-phosphate (SIP), and
Neuropeptides: [0019] Z is at least one bone-targeting molecule;
and [0020] Y is an optional linker that joins and/or links X and Z;
[0021] or a pharmaceutically acceptable salt thereof, or a
metabolite thereof. [0022] 2. The compound according to claim 1,
wherein [0023] Z is at least one polypeptide comprising 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and/or 20 acidic amino acid
residues. [0024] 3. The compound according to claims, 1-2 wherein Z
includes multiple aspartates and/or multiple glutamates. [0025] 4.
The compound according to claim 3, wherein Z is comprised of at
least one polypeptide selected from the group consisting of: at
least 5 aspartic acids, at least 5 glutamic acids, at least 10
aspartic acids, at least 10 glutamic acids, at least 20 aspartic
acids, at least 20 glutamic acids. [0026] 5. The compounds
according to claims 1-4, wherein Z is selected from the group
consisting of: a polypeptide comprising 10 aspartic acid residues
(SEQ ID NO. 23) and a polypeptide comprising 10 glutamic acid
residues (SEQ ID NO. 24). [0027] 6. The compound according to
claims 1-4, wherein Z is at least one polypeptide comprising 4 or
more acidic amino acid residues, polyphosphate, aminohexanedioic
acid or derivatives thereof, and/or alendronate or derivatives
thereof. [0028] 7. The compound according to claims 1-6, wherein Y
is selected from the group consisting of: releasable linkers and
non-releasable linkers. [0029] 8. The compound according to claim
7, wherein the releasable linker includes at least of the following
groups: a disulphide, an ester, or a Protease specific amide bond.
[0030] 9. The compound according to claim 7, the non-releasable
linker includes at least one of the following groups; a
carbon-carbon bond, or an amide. [0031] 10. The compound according
to claims 1-6, wherein Y is polyethylene glycol (PEG). [0032] 11.
The compound according to claim 10, wherein the PEG linker is
comprised of 2-8 oxyethylene units. [0033] 12. The compound
according to claims 1-6, wherein Y is a peptide belonging to the
natural sequence of Z. [0034] 13. The compound according to claims,
1-9, wherein the Src1 inhibitor is at least one compound selected
from the group consisting of: Dasatinib, and E739. [0035] 14. The
compound according to claims, 1-9, wherein the SIP is least one
compound selected from the group consisting of: Ozanimod (SIP1R
agonist), and 4-deoxypyridoxine (DOP) (SIP lyase inhibitor). [0036]
15. The compound according to claims, 1-9, wherein the
Neuropeptide, is at least one compound selected from the group
consisting of: Substance P, vasoactive intestinal peptide (VIP),
Pituitary adenylate cyclase-activating polypeptide (PACAP), Amylin
(1-8) and Calcitronin gene like related peptide (CGRP). [0037] 16.
The compound according to claims, 1-9, wherein the Osteogenic
peptide is histone h4. [0038] 17. Use of a compound according to
any of claims 1-16, for the manufacture of a medicament for
therapeutic application.
[0039] A method of treating a patient, comprising the step of
administering at least one dose of a compound according to claims
1-16. These and other features, aspects and advantages of the
present disclosure will become better understood with reference to
the following figures, associated descriptions and claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0040] FIG. 1 depicts the bone volume divided by total volume of
the 100 thickest micro computed tomography (CT) slices of the
fracture callus bone density ("BV/TV") using a Dasatinib and
targeted Dasatinib conjugate (both 10 .mu.mol/kg). Both were
subcutaneously dosed daily to fracture-bearing Notre Dame breed
(ND4) of Swiss Webster mice. Bone density of the fracture callus
from the targeted Dasatinib group is twice as dense as the saline
group, and 50% denser than the free Dasatinib group.
[0041] FIG. 2 depicts BV/TV and Trabecular Thickness using targeted
E738 conjugate (1 mol/kg), subcutaneously dosed every-other-day to
fracture-bearing Charles River's breed (CFW) of Swiss Webster mice.
Targeted E738 conjugate significantly improved the bone density and
trabecular thickness at the fracture callus.
[0042] FIG. 3 depicts structures for Dasatinib and E738.
[0043] FIG. 4 depicts structures for targeted conjugates of
Dasatinib and E738.
[0044] FIG. 5 depicts peak load of Fractured Femurs after 2
weeks.
[0045] FIG. 6 depicts BV/TV two weeks after fractured femur
received various concentration of Preptin D10 treatment.
[0046] FIG. 7 depicts TbTh (the trabecula thickness of the 100
thickest micro CT slices of the fracture callus) two weeks after
fractured femur received various concentration of Preptin D10
treatment.
[0047] FIG. 8 depicts BV (the overall bone volume of the 100
thickest micro CT slices of the fracture callus) two weeks after
fractured femur received various concentration of Preptin D10
treatment.
[0048] FIG. 9 depicts BV/TV two weeks after fractured femur
received various concentration of OGPD10.
[0049] FIG. 10 depicts TbTh two weeks after fractured femur
received various concentration of OGP D10.
[0050] FIG. 11 depicts TbSp (the spacing between the trabecula in
the 100 thickest micro CT slices of the fracture callus) two weeks
after fractured femur received various concentration of OGP
D10.
[0051] FIG. 12 depicts BV/TV two weeks after fractured femur
received various concentration of BFPD10.
[0052] FIG. 13 depicts TbSp two weeks after fractured femur
received various concentration of BFPD10.
[0053] FIG. 14A depicts BV/TV four weeks after a fractured femur
received various concentration of substance P4 mini peg D10; FIG.
14B depicts the max load of substance P4 D10 four weeks after a
fractured femur received the max load of substance P4 D10.
[0054] FIG. 15 depicts BV/TV four weeks after fractured femur
received various concentration of Ghrelin D10.
[0055] FIG. 16 depicts BV four weeks after fractured femur received
various concentration of pBMP9 D10.
[0056] FIG. 17 depicts BV/TV four weeks after fractured femur
received various concentration of pBMP9 D10.
[0057] FIG. 18 depicts BV/TV four weeks after fractured femur
received various concentration of CNP D10.
[0058] FIG. 19 depicts BV/TV four weeks after fractured femur
received 1 nmol/day of ODP D10.
[0059] FIG. 20 depicts BV/TV three weeks after fractured femur
received various concentrations of CBM D10 as compared to a
fractured femur that received parathyroid hormone 1-34 (PTH).
[0060] FIG. 21 depicts BV/TV four weeks after fractured femur
received various concentrations of P4 D10.
[0061] FIG. 22 depicts BV four weeks after fractured femur received
1 nmol/day of P4 D10.
[0062] FIG. 23 depicts BV/TV four weeks after fractured femur
received various concentrations of MGF D10.
[0063] FIG. 24 depicts BV/TV four weeks after fractured femur
received various concentrations of TP 508_D10.
[0064] FIG. 25a depicts BV/TV four weeks after fractured femur
received 1 nmol/day of VIP_D10.
[0065] FIG. 25b depicts TbTh four weeks after fractured femur
received 1 nmol/day of VIP_D10.
[0066] FIG. 26a depicts BV/TV three weeks after fractured femur
received 0.05 nmol/day, 0.1 nmol/day, and 0.5 nmol/day of
VIP_D10.
[0067] FIG. 26b depicts Max Load three weeks after fractured femur
received 0.05 nmol/day, 0.1 nmol/day, and 0.5 nmol/day of
VIP_D10.
[0068] FIG. 26c depicts Work to Fracture three weeks after
fractured femur received 0.05 nmol/day, 0.1 nmol/day, and 0.5
nmol/day of VIP_D10.
[0069] FIG. 27 depicts the structure for BMP9 (SEQ ID NO: 14).
[0070] FIG. 28 depicts the structure for Ghrelin D10 (SEQ ID NO:
15).
[0071] FIG. 29 depicts the structure for Preptin D10 (SEQ ID NO:
3).
[0072] FIG. 30 depicts the structure for CNP-D10 (SEQ ID NO:
16).
[0073] FIG. 31 depicts the structure for VIP D10 (SEQ ID NO:
17).
[0074] FIG. 32 depicts the structure for Substance P with 4 mini
PEG conjugated to D10 (SEQ ID NO: 18).
[0075] FIG. 33 depicts the structure for CBM D10 (SEQ ID NO:
9).
[0076] FIG. 34 depicts the structure for ODP D10 (SEQ ID NO:
19).
[0077] FIG. 35 depicts the structure for Ozanimod.
[0078] FIG. 36 depicts the structure for DOP.
[0079] FIG. 37 depicts the structure for D.sub.10-Ozanimod.
[0080] FIG. 38 depicts the structure for D.sub.10-DOP.
[0081] FIG. 39 depicts BV/TV 3 weeks after fractured femur received
various concentrations of D.sub.10-DOP.
[0082] FIG. 40 depicts alkaline phosphatase (ALP) activity of
MC3T30E1 cells following exposure to ozanimod of various
concentrations.
[0083] FIG. 41 depicts BV/TV 3 weeks after fractured femur received
various concentrations of D.sub.10-Ozanimod.
[0084] FIG. 42 depicts BV/TV 3 weeks after fractured femur received
various concentrations of PACAP (D)E.sub.10.
[0085] FIG. 43 depicts Max Load 3 weeks after fractured femur
received various concentrations of PACAP (D)E.sub.10.
[0086] FIG. 44 depicts Stiffness 3 weeks after fractured femur
received various concentrations of PACAP (D)E.sub.10.
[0087] FIG. 45 depicts the sequence for Amylin(1-8) D.sub.10 (SEQ
ID NO: 20).
[0088] FIG. 46 depicts BV/TV 3 weeks after fractured femur received
various concentrations of Amylin(1-8)
[0089] FIG. 47 depicts Max Load 3 weeks after fractured femur
received various concentrations of Amylin(1-8) D.sub.10.
[0090] FIG. 48 depicts Work to Fracture 3 weeks after fractured
femur received various concentrations of Amylin(1-8) D.sub.10.
[0091] FIG. 49 depicts the sequence for CGRP E.sub.10 (SEQ ID NO:
21).
[0092] FIG. 50 depicts BV/TV 3 weeks after fractured femur received
various concentrations of CGRP E.sub.10.
[0093] FIG. 51 depicts BV 3 weeks after fractured femur received
various concentrations of CGRP
[0094] FIG. 52 depicts Max Load 3 weeks after fractured femur
received various concentrations of CGRP E.sub.10.
[0095] FIG. 53 depicts Work to Force 3 weeks after fractured femur
received various concentrations of CGRP E.sub.10
[0096] FIG. 54 depicts the sequence for PACAP (D)E.sub.10 (SEQ ID
NO: 22).
BRIEF DESCRIPTION OF THE SEQUENCES
[0097] SEQ ID NO: 1: bone forming peptide conjugated with 10
aspartate acids (BFP D10).
[0098] SEQ ID NO: 2: osteogenic growth peptide conjugated with 10
aspartate acids (OGP D10).
[0099] SEQ ID NO: 3: Preptin conjugated with 10 aspartate acids
(Preptin D10).
[0100] SEQ ID NO: 4: substance P with 4 mini PEG linker and
conjugated with 10 aspartate acids (substance P 4 mini PEG
D10).
[0101] SEQ ID NO: 5: Ghrelin D10 with Serine (Ser)-3 replaced with
diaminopropinoic acid.
[0102] SEQ ID NO: 6: BMP9 D10.
[0103] SEQ ID NO: 7: C-type Natriuretic peptide (CNP) conjugated
with 10 aspartate acids (CNP 10).
[0104] SEQ ID NO: 8: Vasoactive intestinal peptide conjugated with
D10.
[0105] SEQ ID NO: 9: collagen binding motif conjugated with 10
aspartate acids (CBM D10).
[0106] SEQ ID NO: 10: P4 conjugated with 10 aspartate acids (P4
D10).
[0107] SEQ ID NO: 11: Mechano-growth factor conjugated with 10
aspartate acids (MGF D10).
[0108] SEQ ID NO: 12: Thrombin fragment TP508 conjugated with 10
aspartate acids (TP 508 D10).
[0109] SEQ ID NO: 13: Osteopontin-derived peptide conjugated with
10 aspartate acids (ODP D10).
[0110] SEQ ID NO: 14: BMP9 (BMP9).
[0111] SEQ ID NO: 15: Ghrelin D10 (Ghrelin D10).
[0112] SEQ ID NO: 16: CNP-D10.
[0113] SEQ ID NO: 17: VIP D10.
[0114] SEQ ID NO: 18:4 mini PEG D10.
[0115] SEQ ID NO:19: ODPD10.
[0116] SEQ ID NO: 20: Pituitary Adenylyl Cyclase Activating Peptide
(PACAP)_conjugated with 10 aspartate acids (PACAP-(D)E.sub.10).
[0117] SEQ ID NO: 21: Pituitary Adenylate Cyclase-Activating
Peptide conjugated with 10 aspartate acids (Amylin 1-8).
[0118] SEQ ID NO: 22: Calcitonin Gene-Rated Peptide (CGRP)
conjugated with 10 glutamic acids (CGRP-E.sub.10).
[0119] SEQ ID NO: 23: Targeting group consisting of a polypeptide,
DDDDDDDDDD.
[0120] SEQ ID NO: 24: Targeting group consisting of a polypeptide,
EEEEEEEEEE
DETAILED DESCRIPTION
[0121] While the concepts of the present disclosure are illustrated
and described in detail in the figures and the description herein,
results in the figures and their description are to be considered
as examples and not restrictive in character; it being understood
that only the illustrative aspects are shown and described and that
all changes and modifications that come within the spirit of the
disclosure are desired to be protected.
[0122] Unless defined otherwise, the scientific and technology
nomenclatures have the same meaning as commonly understood by a
person in the ordinary skill in the art pertaining to this
disclosure.
[0123] Aspects of the fracture targeted technology disclosed herein
can help both civilians and military personnel. Bone fractures
occur at an annual rate of 2.4 per 100 people and cost the US
healthcare system approximately $28 billion per year. Of the 6.3
million bone fractures that occur annually in the US, 300,000
result in delayed union or non-union healing. Approximately 887,679
hospitalizations result each year from fractures. Over half (57%)
of fractures resulting in hospitalizations occur in persons aged 65
and over. Estimated health care costs are indicated in Table 1,
below.
TABLE-US-00001 TABLE 1 Cost without Cost with Fracture Healing time
surgery surgery Leg 10-12 weeks) $2,500 $16,000 Hip 12+ weeks
$11,500 $66,500 Vertebral (8+ weeks) $5,000-15,000 $50,000-150,000
Arm 6-10 weeks $2,500 $16,000
[0124] Currently, a substantial fraction of national defense
outlays is devoted to combat-related medical expenditures, with a
significant proportion of these costs devoted to treatment of
orthopedic injuries. Indeed, .about.65% of all wounds associated
with military conflicts since WWI have included orthopedic
injuries, and 26% of all injuries to an extremity have involved one
or more broken bones. Treatment of bone fractures not only removes
a soldier from service for an extended period of time, but also
requires the attention of multiple additional personnel to treat,
monitor and rehabilitate the injured soldier. Unfortunately, some
orthopedic injuries are so severe that resolution of the damage
never occurs, and the armed services are then obligated to care for
the damaged combatant in perpetuity.
[0125] Fractured bones are not only an adverse consequence of
combat, they also constitute a prominent repercussion of military
training exercises. During the course of a soldier's schooling, a
female recruit will have a 3.4-21% chance of suffering a stress
fracture, while a male recruit will have a 1-7.9% probability of
experiencing the same injury. While such maladies may at first seem
trivial, statistics reveal that they cost the military
.about.$34,000 per soldier which totals up to .about.$100 million
in aggregate per year. Not surprisingly, many affected recruits
eventually leave the military as a consequence of their stress
fracture, which results in further expenses arising from wasted
recruiting and training efforts. Therapies for fractured bones both
within and outside of the military rely almost exclusively on
mechanical stabilization of the damaged bone (i.e. use of a cast,
pin, rod, or plate, etc.). In fact, the only FDA-approved drug for
enhancing fracture repair is a bone anabolic agent that must be
applied topically to the fracture surface during surgery. Needless
to say, such a therapy is inappropriate when the surgery is not
otherwise indicated, can only be administered once (i.e. during the
brief period when the fracture surface is exposed), cannot be
easily adapted for treatment of multiple fractures, and is never
used for therapy of stress fractures. What is critically needed is
obviously a systemically administered bone anabolic agent (i.e. as
drug that can stimulate rapid bone fracture healing) that will
concentrate selectively on the bone fracture surface and induce
accelerated bone formation only at the damaged site. Surprisingly,
nothing of this sort has ever been described in the literature.
[0126] Recognizing the enormous need for a systemically
administered bone fracture-targeted healing agent, peptides and
other molecules with structures that home specifically to bone
fracture surfaces following intravenous or subcutaneous
administration were identified. A second group of bone anabolic
agents (for example, both bone growth stimulating hormones and
cytokines as well as various low molecular weight bone
growth-inducing drugs, etc.), that when linked to one of our bone
fracture-homing peptides, would promote accelerated fracture
repair, were also identified. Fortunately, several
fracture-targeted bone anabolic drugs met all initial requirements
for advancement into large animal studies. That is, the targeted
conjugates were found to: i) reduce the time for fractured femur
repair in mice by roughly half, ii) induce no detectable systemic
toxicity at its effective dose, iii) cause no ectopic bone
formation at either the injection site or elsewhere), iv) lead to
regeneration of bone at the fracture site that was biomechanically
stronger than the contralateral (unbroken) femur, and v) result in
eventual remodeling of the fractured region into normal cortical
bone.
[0127] All in vivo data included herein are from swiss Webster
mice. All mice received an osteotomy on their right femur and
received subcutaneous drug administration daily for either 2, 3 or
4 weeks, as indicated, for each compound. 1.times. concentration
represents 1 nmol/day, 10.times. represents 10 nmol/day, 100.times.
represents 100 nmol/day most studies have an n of 5.
[0128] Aspects of the disclosure include conjugates sometimes
written in the form of X-Y-Z, wherein each conjugate includes at
least one moiety (X) that has the ability to effect bone growth,
development and/or healing, for example, anabolic agents, and a
targeting moiety (Z) which has an affinity for bone and helps to
direct the conjugate to bone. In some of these conjugates, the X
and Z portions are joined together by a linker region (Y).
[0129] Targeting moieties (Z), many of which are explicit or
implicit disclosed herein, have the potential to target bone
anabolic agents to bone fractures, ostectomies, and osteotomy
sites. The compounds described here are composed of molecules with
high affinity towards hydroxyapatite and a bone anabolic agent.
Although targeting has been exemplified primarily with acidic
oligopeptides, all molecules with affinity towards hydroxyapatite
could be attached to a bone anabolic agent to improve fracture
repair. These molecules include but are not limited to ranelate,
bisphosphonates, tetracyclines, polyphosphates, molecules with
multiple carboxylic acids, calcium chelating molecules, metal
chelators, acidic amino acid chains of either d or L chirality.
Each of the previously listed targeting molecules can be single
units, polymers, dendrimers or multiple units. Other molecules can
also be substituted for the targeting agent. These include
peptides, proteins and manmade molecules that intercalate, bind to,
adsorb to, or hybridize with: collagen, the extracellular matrix,
heparan sulfate, chondroitin sulfate, keratan sulfate, hyaluronic
acid, elastin, fibronectin, laminin, proteoglycans, basement
membrane, extracellular polymeric substances, integrins, blood
clotting factors, fibrinogen, thrombin, fibrin, and other
extracellular macromolecules, It is also possible to target using a
combination of the listed targeting molecules.
Definitions
[0130] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as is commonly understood by one
of ordinary skill in the art to which this disclosure pertains.
[0131] The term "BV/TV" means the bone volume divided by total
volume of the 100 thickest micro CT slices of the fracture
callus.
[0132] The term "TbTh" means the trabecular thickness of the 100
thickest micro CT slices of the fracture callus.
[0133] The term "By" means the overall bone volume of the 100
thickest micro CT slices of the fracture callus.
[0134] The term "TbSp" means the spacing between the trabecula in
the 100 thickest micro CT slices of the fracture callus.
[0135] The term "Peak Load" means a postmortem 4 point bend of the
healed femur. Peak load represents the maximum force the healed
femur withstood before it refractured.
[0136] The term "D10" at the end of any name represents that the
peptide is targeted to bone by a chain of 10 aspartic acids. D10
can be at the N-terminus or C-terminus of the specified
peptide.
[0137] The term "E10" of "(D)E10" at the end of any name represents
that the peptide is targeted to bone by a chain of 10 (D) glutamic
acids.
[0138] The term "mp4" in the middle of any name represents that the
therapeutic is linked to the targeting peptide via a polymer of 4
minipegs aka 8-Amino-3,6-Dioxaoctanoic Acid.
[0139] The term "P4" means a fragment that represents the knuckle
epitope in hBMP-2.
[0140] The term "P-4" corresponds to residues 73-92 of BMP-2 in
which Cys-78, Cys-79, and Met-89 are changed to Ser, Ser, and
threonine (Thr). BMPs are well known regulators of bone and
cartilage formation. BMPs bind as dimers to type I and type II
Ser/Thr receptor kinases, forming an oligomeric complex that
activates intracellular small mothers against decapentaplegic
(Smad) proteins leading to their translocation into the nucleus
where they serve as transcription factors to activate different OB
differentiation markers (such as Runx2), leading to
osteoblastogenesis. BMPs have also been shown to stimulate
mesenchymal stem cells (MSC) differentiation to OBs by promoting
recruitment of osteoprogenitor cells.
[0141] Compounds which effect bone growth and may be used to
practice aspects of the present disclosure include but are not
limited to the following: growth factors, fragments of
neuropeptides or neurotransmitters, synthetic peptides or small
molecules that mimic the action of neuropeptides or
neurotransmitters, a sarcoma (SRC) kinase inhibitor peptides or
small molecules that inhibits the activity of SRC kinase, or a
sphingosine-1-phosphate receptors (S1P-R) modulator kinase
inhibitor peptides or small molecules that modulates the activity
of S1P-R. Examples of which may include but are not limited to:
PACAP, VIP, Calcitonin, Calcitonin gene like peptide, amylin,
Neuropeptide Y, Serotonin, Dopamine, SSRIs, Purines and
pyrimidines, Glutamate, norepinephrine, epinephrine, Substance P,
Nerve growth factor, Dasatinib Imatinib, Saracatinib (AZD0530),
Bosutinib (SKI-606), KK2-391, NVP-BHG712, PP2, PP121, PP1, MNS
(3,4-Methylenedioxy-beta-nitrostyrene), UM-164, Repotrectinib,
WH-4-023, CCT196969, MLR-1023, SU6656, AD80, eCF506, AZM 475271,
Herbimycin A, KB SRC 4, Lavendustin A (RG 14355), SU 6656, S1P,
FTY720, AAL(R), KRP-203, Ceralifimod, ponesimod, siponimod, or
CYM-5442, RP-001.
Bone Growth Modifiers and Delivery Peptides
TABLE-US-00002 [0142] BFP1D10 (SEQ ID NO: 1)
DDDDDDDDDDGQGFSYPYKAVFSTQ
[0143] BFP (bone forming Peptide) a fragment of immature BMP7 is a
15-amino acid peptide corresponding to residues 100-115 of the
immature form of BMP-7 which like BMP2 is involved in osteogenic
differentiation, proliferation, and formation of new bone. This
short peptide also induces osteogenesis calcium content in
MSCs.
BMP-9
[0144] BMP-9 is also a potent regulator of osteogenesis and
chondrogenesis and is a potent inducer of differentiation of
osteoblasts. pBMP9 is a 23-residue peptide derived from residues
68-87 of the knuckle epitope of human BMP-9. The mechanism of
action of this peptide is likely to involve the Smad pathway. The
structure of BMP9 is depicted in FIG. 27.
Ghrelin D10
[0145] Ghrelin is a 28-residue peptide hormone synthesized
primarily by the gastric fundus in response to fasting, and acts as
a ligand of the growth hormone secretagogue (GHS) receptor (GHSR)
to promote growth hormone release from the pituitary. Ghrelin
stimulation at the GHSR leads to the proliferation of osteoblasts
and prevents the apoptosis of osteoblasts through mitogen-activated
protein kinase/extracellular signal-regulated kinases (MAPK/ERK)
and phosphoinositide 3-kinase/protein kinase B (PKB) (PI3K/AKT)
pathways. Ghrelin also stimulates osteoprotegerin (OPG) gene
expression, which inhibits the coupling between the osteoclasts and
Osteoblasts, leading to reduced osteoblast-related osteoclast
differentiation. Increased OPG also and decreases osteoclast
activity. Ghrelin is only active when the Ser-3 is acylated with
octanoic acid. Our construct contains a stabilized version of this
where Ser-3 was replaced with diaminopropionic acid. The structure
of Ghrelin D10 is depicted in FIG. 28.
Preptin D10
[0146] Preptin is a 34-residue peptide hormone that is secreted by
the .beta.-cells of the pancreatic islets. This peptide corresponds
to Asp-69 to Leu-102 of the E-peptide of proinsulin-like growth
factor-II (pro-IGF-II). Preptin's anabolic effects on bone are
exerted through its ability to stimulating osteoblasts s
proliferation, differentiation, and promoting their survival.
Preptin's proliferative effect is predicted to be facilitated
through a G-protein-coupled receptor triggering phosphorylation of
p42/44 MAP kinases. Some of Preptin's anabolic effects are believed
to be due to it stimulating an increase in a known bone anabolic
connective tissue growth factor. While the native peptide effects
glucose metabolism the first 16 amino acids are important for its
anabolic effects and have no effects on glucose metabolism. The
structure of Preptin D10 is depicted in FIG. 29.
CNP-D10 is a C-Type Natriuretic Peptide Targeted with D10
[0147] C-Type Natriuretic Peptide (CNP) contains 22 residues
stabilized by an intramolecular disulfide linkage between Cys-6 and
Cys-22 it functions as a local regulator of vascular tone, possibly
due to its strong vasorelaxant properties. CNP also acts on the
differentiation and proliferation of OBs, OCs, and chondrocytes via
an autocrine/paracrine process through binding to the natriuretic
peptide receptor B (NPR-B). CNP activates bone turnover and
remodeling. Endochondral ossification is another mechanism of bone
formation affecting chondrocytes. It involves the conversion of an
initial cartilage template into bone such as long bones and
vertebrae. CNP has been shown to be an important anabolic regulator
of endochondral ossification. The structure of CNP-D10 is depicted
in FIG. 30.
VIP D10 is Vasoactive Intestinal Peptide Targeted with D10
[0148] Vasoactive intestinal peptide (VIP), a neuropeptide that
consists of 28 amino acids and originally isolated from porcine
intestine. VIP has several effects however its receptors are
present on the nerves that rapidly innervate the fracture callus.
It has been shown to be an important regulator of bone formation.
VIP exerts its biological effects through the G-protein-coupled
receptors (VPAC1, VPAC2, and PAC1). Signaling through these
receptors also enhanced cell osteoblast differentiation and
proliferation. It also increases expressions of collagen type I,
osterix, and ALP through signaling at the VPAC2 receptor by
triggering an increase in intracellular calcium. VIP also increases
the expressions of BMPs and the nuclear presence of Smad1
transcription factor, which can activate various bone-specific
genes. VIP also enhances osteoblast proliferation and
mineralization through increased gap junction intercellular
communication (GJIC) between osteoblasts. VIP also affects the
differentiation of osteoclasts thus leading to an increase in bone
resorption. The structure of VIP D10 is depicted in FIG. 31.
Substance P with 4 Mini PEG Conjugated to D10
[0149] Substance P- is an 11-amino acid long pro-inflammatory
neuropeptide belonging to the tachykinin family. Substance P
improves mineralization of osteoblasts and the expression of
osteogenic markers at late-stage bone formation, by activating
neurokinin-1 receptor, a G-protein coupled receptor found in the
central and peripheral nervous systems. Also, substance P reduces
osteoclastogenesis and bone resorption. Substance P upregulates the
expressions of collagen type 1, ALP, Runx2 and osteocalcin in
osteoblasts this effect involves the activation of
Wnt/.beta.-catenin signaling pathway. Substance P promotes
differentiation and migration capability of rat bone marrow MSCs
and activates BMP-2 expression in osteoblasts. Some of substance
P's anabolic effects are attributed to in human to increases in
osteoblast proliferation and mineralization through increased gap
junction intercellular communication between osteoblasts. Gap
junction intercellular communication has important roles in
conveying the anabolic effects of hormones and growth factors and
regulating transcription of osteogenic markers. The structure of
Substance P with 4 mini PEG conjugated to D10 is depicted in FIG.
32.
CBMD10-is the Collagen Binding Motif of Osteopontin Targeted by
D10
[0150] CBM collagen binding motif is the highly conserved
28-residue collagen binding motif (CBM) (residues 150-177) of human
osteopontin. Osteopontin, a glycosylated phosphoprotein prominently
localized in the extracellular matrix (ECM) of mineralized bone
tissue to form a complex with collagen in bone tissue, thereby
inducing mineralization of collagen fibrils. CBM enhances
osteoblast differentiation of human MSC. CBM causes osteogenic
differentiation of human bone marrow MSCs and increases mineralized
of bone. CBM works in human MSCs by increasing extracellular Ca'
influx, which leads to the activation of CaMKII and the subsequent
phosphorylation of ERK1/2, ultimately influencing OB
differentiation. The structure of VIP D10 is depicted in FIG.
33.
ODPD10
[0151] Osteopontin-derived peptide (ODP), a 15-residue peptide
derived from rat osteopontin. ODP like CBM is a fragment of
extracellular protein involved in the mineralization of collagen.
ODP enhanced the differentiation and mineralization of MSCs. ODP
improves the attachment via receptor mediated attachment and
migration of osteoblasts and fibroblasts to the fracture site. ODP
improves the proliferation and migration of osteoblasts. Though the
signaling pathways aren't completely elucidated for this molecule
its believed that it works in a similar mechanism as CBM. The
structure of ODPD10 is depicted in FIG. 34.
TABLE-US-00003 OGP-D10 (SEQ ID NO: 2) DDDDDDDDDDALKRQGRTLYGFGG
[0152] OGP-targeted Osteogenic growth peptide (OGP) is composed of
a 14-aa residue identical to the C-terminus of histone 4 conjugated
to an acidic oligopeptide at the N-terminus. Systemic
administration of free OGP has been shown to improve fracture
repair by improving the mineralization of cartilaginous fracture
callus.
TABLE-US-00004 (SEQ ID NO: 11)
MGF-DDDDDDDDDDYQPPSTNKNTKSQRRKGSTFEEHK
[0153] Targeted mechano growth factor (MGF) E peptide is a splice
variant of insulin-like growth factor I (IGF-I) with a targeting
acidic oligopeptide on the N terminus. MGF causes osteoblast
proliferation through the MAPK-ERK signaling pathway. Local
injections (57 ug/kg) in rabbit bone defects (5 mm) demonstrated
accelerated healing through osteoblast proliferation.
TABLE-US-00005 (SEQ ID NO: 12)
TP508-DDDDDDDDDDAGYKPDEGKRGDACEGDSGGPFV
[0154] Targeted TP-508 is a prothrombin peptide that has been
modified on the N-terminus with an acidic oligopeptide. The
anabolic portion of TP-508 has been used in clinical trials for
repairing foot ulcers. Free tp-508 has a proliferative effect on
osteoblasts. Local injections have demonstrated accelerated
fracture repair in older rats.
Sphingosine-1-Phosphate (S1P)--S1P Lyase Inhibitor (DOP) and S1PR1
Agonist (Ozanimod)
[0155] Sphingosine-1-phosphate (S1P) is an important extracellular
signaling molecule that mediates a variety of physiological
functionalities. There are five cell-surface receptors responsible
for the downstream signaling pathways related to S1P, namely S1PR1
to S1PR5. In particular, the S1P-S1PR1 and S1P-S1PR2 axes are
essential in bone metabolism. It has been reported that S1PR1
knockdown would lead to reduced trabecular thickness and trabecular
density in vivo, resulting in an osteoporotic phenotype.1
Meanwhile, S1PR2 signaling boosts OPG production and promotes
osteoblast differentiation, which in turn facilitates bone
formation. Naturally, stimulation of S1P signaling at the fracture
site might promote bone growth.
[0156] Small molecule agonists for S1P receptors have been widely
reported. S1P lyase is the sole enzyme responsible for the
irreversible degradation of S1P. The inhibition of this enzyme
would increase the availability of S1P, resulting in enhanced S1P
signaling. Targeted delivery of a S1P inhibitor or a S1PR1 agonist
to the fracture surface would boost S1P signaling at the fracture
site, which might accelerate fracture repair.
[0157] By utilizing a targeted delivery strategy, S1P lyase
inhibitors or S1PR1/S1PR2 agonists were delivered specifically to
the fracture surface for enhanced ability to facilitate fracture
healing. Local injections demonstrated acceleration of fracture
healing from representative S1P lyase inhibitor (DOP) and S1PR1
agonist (ozanimod). The structure of Ozanimod is depicted in FIG.
35. The structure of DOP is depicted in FIG. 36 The structure of
D.sub.10-ozanimod in FIG. 37. The structure of D.sub.10-DOP is
depicted in FIG. 38.
TABLE-US-00006 Pituitary Adenylate Cyclase-Activating Peptide
(D)E.sub.10-PACAP(D)E.sub.10 (SEQ ID NO: 14)
HHSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK
[0158] Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylyl
Cyclase Activating Peptide (PACAP) are two neuropeptides that have
demonstrated an activating and proliferative effect on osteoblasts,
the cells that produce the mineral component of bone. VIP is
important in bone remodeling and has shown stimulating effects on
alkaline phosphatase (ALP), a marker of osteoblast mineralization.
PACAP is capable of affecting osteoblasts independently of VIP, and
in cell cultures has shown osteogenic effects. VIP and PACAP both
act on g-protein coupled receptors VPAC-1 and VPAC-2 with equal
affinity, while PACAP acts on the G-protein coupled receptor (GPCR)
PAC-1 with 1000 times greater affinity. These receptors are found
throughout the body, and VIP and PACAP play roles in the brain,
intestines, immune system, endocrine system, and others as well as
bone. By synthesizing these peptides in sequence with acidic
oligopeptide targeting ligands, accelerated healing and minimized
of off target effects of PACAP are demonstrated by targeting bone
fracture sites. The structure of PACAP (D)E.sub.10 is depicted in
FIG. 54.
Pituitary Adenylate Cyclase-Activating Peptide--Amylin
(1-8)-D.sub.10 (SEQ ID NO 15)
[0159] Amylin is a natural 37 amino acid peptide formed primarily
by the .beta.-cells of the pancreatic islets. It comprises an
amidated C-terminus and a disulfide bond between the Cys residues
at sites 2 and 7 in the primary sequence. The present compound is
amino acid 1-8 of the native sequence attached to 4 peg2 spacers
then attached to ten aspartic acid to home it to hydroxyapatite.
Amylin is structurally homologous to calcitonin gene-related
peptide (CGRP) and more distantly to calcitonin itself. Like
calcitonin, amylin was found to decrease Osteoclasts (OC)
development in mouse bone marrow cultures, stimulate adenosine
monophosphate (AMP) formation, induce quiescence in OCs, and thus,
reducing the extent of bone resorbed. In addition to its activity
on OCs, amylin has also been found to affect osteoblasts (OB),
possibly through an increase of cAMP and the activation of
MAPK/protein kinase C signaling pathway. The structure for Amylin
(1-8) is depicted in FIG. 45.
Calcitonin Gene-Related Peptide (CGRP) (SEQ ID NO 16)
[0160] The targeted construct of CGRP is the full natural 37 amino
acids with the 2nd and 7th amino acids cyclized then on the C
terminus is 4 minipeg spacers followed by ten D glutamic acids.
[0161] Primary afferent sensory nerve fibers within the periosteum
release peptides important for osteogenesis including the
osteoanabolic neuropeptide, CGRP (calcitonin gene-related peptide).
Thus, activation of sensory nerves release or exogenous treatment
with CGRP is demonstrated to accelerate bone fracture repair by
localizing it just to the bone fracture site. The structure of CGRP
is depicted in FIG. 49. CGRP is also demonstrated to improve
fracture healing, likely through promotion of both osteogenic
differentiation and angiogenesis. Its effect can also be
contributed to a potential decrease in osteoclasts.
Material and Methods
Solid Phase Peptide Synthesis
[0162] Unless noted otherwise, the conjugates of the present
disclosure are synthesized using the following synthesis. In a
solid phase peptide synthesis vial capable of bubbling nitrogen,
Wang resin (0.39 mmol/g) was loaded at 0.39 mmol/g with the first
amino acid overnight in dichloromethane (DCM) and
diisopropylethylamine (DIPEA). The resin was then capped with
acetic anhydride and pyridine for 30 minutes, followed by three
washes of DCM and dimethylformamide (DMF), respectively. Following
each amino acid coupling reaction, fluorenylmethyloxycarbonyl
(Fmoc)-groups were removed by three 10 minute incubations with 20%
(v/v) piperidine in DMF. The resin was then washed 3.times. with
DMF prior to the next amino acid being added. Each amino acid was
added in a 5-fold excess with
N,N,N',N'-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium
hexafluorophosphate (HBTU)/DIPEA. Upon completion of the synthesis,
peptides were cleaved using 95:2.5:2.5 trifluoroacetic
acid:water:triisopropylsilane. Cysteine containing peptides were
cleaved using 95:2.5:2.5 trifluoroacetic
acid:triisopropylsilane:water: and 10 fold
tris(2-carboxyethyl)phosphine (TCEP).
Small Molecules Synthesis
[0163] For the initial loading of the solid phase peptide synthesis
(SPPS) resin, 2-chlorotrityl chloride resin (0.4 g, 1.4 mmol/g) was
swollen in DCM (10 mL/g resin) followed by addition of
Fmoc-L-Asp(OtBu)-OH (1.15 g, 2.8 mmol) and DIPEA (1.66 mL, 9.5
mmol) dissolved in DCM (14 mL). The mixture was agitated by
bubbling argon for 1 hour, after which the solution was drained
before 20 mL of capping cocktail (DCM:MeOH:DIPEA=17:2:1) was added
and the solution was again bubbled for 20 minutes. The resin was
then subjected to standard washing procedures which consisted of
washes with DMF (3 times), DCM (3 times) and isopropyl alcohol
(IPA) (3 times) following each coupling reaction, and washes with
DMF (3 times) following each deprotection. After the initial
loading, all subsequent coupling reactions were performed with
solutions of Fmoc-L-Asp(O-tert-butyl)-OH (1.15 g, 2.8 mmol) or
Fmoc-S-trityl-L-cysteine (1.64 g, 2.8 mmol), PyBOP (1.42 g, 2.75
mmol), and DIPEA (1.66 mL, 9.5 mmol) in DMF (14 mL). One-hour
standard coupling time was used for all aspartic acid and cysteine
residues. Fmoc-deprotection was done with 20% piperidine solution
in DMF for two sessions of 5 minutes and 10 minutes each. The
11-mer peptidic product was cleaved off the resin using a cleavage
cocktail consisting of 90% trifluoroacetic acid (TFA), 3.3%
triisopropyl silane (TIPS), 3.3% water and 3.3% ethane dithiol
(EDT). Following cleavage, the crude product was concentrated under
reduced pressure to remove most TFA, water, TIPS, and EDT, and then
washed 3.times. with ethyl ether (Et.sub.2O), dried under reduced
pressure for 24 hours to give 1 as a white powder (680 mg, 81.3%
overall yield, 98.1% average coupling efficiency).
[0164] 3-maleimidopropionic acid (200 mg, 1.18 mmol) and
benzotriazole-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate
(PyBOP) (572 mg, 1.10 mmol) were dissolved in 5 mL anhydrous DMF in
a 50-mL round-bottom flask degassed with argon. The flask was
cooled on ice and diisopropylethylamine (1.03 mL, 5.9 mmol) was
added and stirred for 5 minutes. Dasatinib (360 mg, 0.738 mmol)
dissolved in 2 mL anhydrous DMF was then added dropwise to the
mixture and the reaction mixture was warmed slowly to room
temperature with stirring over the ensuing 4 hours. Ethyl acetate
(.about.50 ml) was added to the reaction flask and the diluted
mixture was washed 2.times. with deionized (DI) water followed by 4
washes with saturated aqueous sodium chloride (NaCl). The organic
phase was then collected, dried over sodium sulfate and
concentrated in vacuo to yield the crude product. The crude product
was purified by flash column chromatography on Teledyne CombiFlash
Rf+ Lumen (0-25% MeOH in DCM) to give 2 as a pale-yellow powder
(320 mg, 68%).
Cyclization Method for Disulfide Bridged Cyclic Peptides
[0165] For CNP, the standard synthesis of the linear form of the
cyclic peptides Fmoc Cystine with Acetamidomethyl protecting group
on the sulfur was used. Then, to cyclize the peptide, the Cys(Acm)
On-Resin was suspended the linear peptide resin in
N,N-dimethylformamide (DMF) (approximately 1 mL/gram of resin).
Then, the resin was treated with 10 equiv. of iodine (I2) in
DMF/H2O 4:1 (v/v), approximately 1 mL/gram of resin). Then, argon
gas was bubbled through the reaction mixture at room temperature
for 40 minutes. Then, the resin was filtered and washed 3 times
with DMF, 2 times with 2% ascorbic acid in DMF, 5 times with DMF,
and 3 times with dichloromethane (DCM). Then, proceeded with normal
n terminal fmoc deprotection and cleavage from the resin with
normal cleavage solution with no TCEP added to preserve the
disulfide bond. The peptides were then as all peptides purified
using reverse phase chromatography on an HPLC using a 0-50% 20 mM
ammonium acetate: acetonitrile gradient. The product was then
identified from the appropriate fraction using LCMS and lyophilized
to recover it from the water: acetonitrile mixture. All compounds
were dissolved in sterile phosphate buffered saline (PBS) at the
appropriate dose concentrations for drug delivery.
General Methods for Obtaining Test Data
[0166] The targeted conjugates were synthesized using standard Fmoc
solid-phase peptide synthesis, as described above. To ensure the
conjugates' activity, mouse pre-osteoblast (MCTC3-E1) cells were
treated with the targeted and untargeted compounds for three days
at concentrations from 1 pM to 100 nM. After three days of
treatment, the cells were harvested, and the RNA was purified from
the cells. Expression levels of ALP, RUNx2 (transcription factor
for osteoblast differentiation), osterix (OSX), osteopontin (OPN),
collagen 1A (Col-1A), OPG, RANKL, sclerostin gene (SOST), and OC
were quantified via quantitative reverse transcription polymerase
chain reaction (RT-qPCR). Once the biological activity of the
conjugates was confirmed, they were tested in vivo in a fracture
model. Aseptic surgical techniques were used to place a 23-gage
needle as in intramedullary nail in the femur of anesthetized,
12-week-old Swiss Webster mice for internal fixation before
fracture. Femur fractures were induced using a drop weight fracture
device from RISystem. The mice received buprenorphine for three
days post fracture. The mice were dosed subcutaneously each day for
three weeks or 17 days. Fracture healing was assessed using microCT
(Scanco Medical Ag). Morphometric parameters were quantified in the
100 widest slices of the fracture callus. Trabecular thickness
(TbTh), trabecular spacing (TbSp), total volume (TV), and volume of
calcified callus (BV) were calculated. Fractured femurs were tested
for strength in a four-point bend to failure using an Electro Force
TestBench (TA Instruments). Lower supports were 10 mm apart on the
anterior face of the femur in contact with the proximal and distal
diaphysis. Upper supports were 4 mm apart and spanned the entire
fracture callus on the diaphysis. Force was applied from the
posterior face of the femur with a displacement rate of 0.3 mm/sec.
Peak load, yield load, stiffness, displacement post yield, work to
fracture, and deformation data were generated. Statistical analysis
was performed using a two-way analysis of variance (ANOVA) and a
Tukey post-hoc analysis with significance reported at the 95%
confidence level. All animal experiments were performed in
accordance with protocols approved by Purdue University's
Institutional Animal Care and Use Committee (IACUC).
EXAMPLES
Example 1. Targeted Delivery of Src Kinase Inhibitors to Fracture
Site for Accelerated Healing
[0167] Example 1 shows representative Src kinase inhibitors
Dasatinib and E738 (structures shown in FIGS. 3-4 respectively)
effectively increased the bone density of the fracture callus when
they are conjugated with acidic aspartic acids. See FIGS. 1-2,
where bone density of the fracture callus from the targeted
Dasatinib group is twice as dense as the saline group, and 50%
denser than the free Dasatinib group; targeted E738 conjugate has
significantly improved the bone density and trabecular thickness at
the fracture callus. The structure of CBM D10 is depicted in FIG.
33.
Example 2. Representative Anabolic Peptides on Peak Load of
Fractured Femurs after Two Weeks
[0168] Example 2 provides the maximum force a representative
anabolic peptide induced healed femur can withstand before it
refractured. As shown in FIG. 5, bone morphogenetic protein pathway
signaling peptide BFP-D10 with 100 nmol/day (100.times.) treatment
obtained the maximum peak load, followed by IGF derived peptide of
Preptin-D10 100.times., and Osteogenic growth peptide (OGP-D10
100.times.), as compared to PBS.
Example 3. Preptin D10 Efficacy on Fracture Healing
[0169] Example 3 indicates Preptin D10 effect on healing fractured
bone after 2 weeks of various concentrations application (1
nmol/day, 10 nmol/day and 100 nmol/day, referred as 1.times.,
10.times. and 100.times. respectively). The healing was reflected
as BV/TV in FIG. 6, TbTh in FIG. 7 and bone volume in FIG. 8, all
in a dose dependent manner.
Example 4. OGP D10 Efficacy on Fracture Healing
[0170] Example 4 indicates osteogenic growth peptide conjugate
(OGP-D10) effect on healing fractured bone after 2 weeks of various
concentrations application (1 nmol/day, and 100 nmol/day, referred
as 1.times., and 100.times. respectively). The healing was
reflected as BV/TV in FIG. 9, TbTh in FIG. 10 and TbSp in FIG. 11,
all in a dose dependent manner.
Example 5. BFP D10 Efficacy on Fracture Healing
[0171] Example 5 indicates bone forming peptide conjugate (BMP-D10)
effect on healing fractured bone after 2 weeks of various
concentrations application (1 nmol/day, 10 nmol/day and 100
nmol/day, referred as 1.times., 10.times. and 100.times.
respectively). The healing was reflected as BV/TV in FIG. 12, and
TbSp in FIG. 13 in a dose dependent manner.
Example 6. Substance P D10 Effect on Fracture Healing
[0172] Example 6 indicates substance P D10 conjugate effect on
healing fractured bone after 4 weeks of various concentrations
application (1 nmol/day, 10 nmol/day and 100 nmol/day, referred as
1.times., 10.times. and 100.times. respectively). The healing was
reflected as BV/TV in FIG. 14A in dose dependent manner. FIG. 14B
indicates the peak load of substance P D10 10.times. induced healed
femur can withstand between 30-35 Newtons force.
Example 7. Ghrelin-D10 Effect on Fracture Healing
[0173] Example 7 indicates Ghrelin-D10 conjugate effect on healing
fractured bone after 4 weeks of various concentrations application
(1 nmol/day, 10 nmol/day and 100 nmol/day, referred as 1.times.,
10.times. and 100.times. respectively). The healing was reflected
as BV/TV in FIG. 15 in dose dependent manner.
Example 8. pBMP9 D10 Effect on Fracture Healing
[0174] Example 8 indicates pBMP9 D10 conjugate effect on healing
fractured bone after 4 weeks of various concentrations application
(1 nmol/day, 10 nmol/day and 100 nmol/day, referred as 1.times.,
10.times. and 100.times. respectively). The healing was reflected
as bone volume in FIG. 16 and BV/TV in FIG. 17 in a dose dependent
manner.
Example 9. CNP D10 Effect on Fracture Healing
[0175] Example 9 indicates C-Type Natriuretic Peptide conjugate CNP
D10 effect on healing fractured bone after 4 weeks of various
concentrations application (1 nmol/day and 10 nmol/day referred as
1.times. and 10.times. respectively). The healing was reflected as
BV/TV in FIG. 18 in a dose dependent manner.
Example 10. ODP D10 Effect on Fracture Healing
[0176] Example 10 indicates osteopontin derived peptide conjugate
ODP D10 effect on healing fractured bone after 4 weeks of 1
nmol/day (referred as 1.times.). The healing was reflected as BV/TV
in FIG. 19.
Example 11. CBM D10 Effect on Fracture Healing
[0177] Example 11 indicates collagen binding motif of osteopontin
conjugate CBM D10 effect on healing fractured bone after 3 weeks of
various concentrations application (0.1 nmol/day, 1 nmol/day and 10
nmol/day, referred as 0.1.times., 1.times. and 10.times.
respectively). The healing was reflected as BV/TV in FIG. 20 in a
dose dependent manner. It is worth noting that the lowest does of
CBM D10 has the similar effect of free PTH, an anabolic drug
without specific bone targeting.
Example 12. P4 D10 Effect on Fracture Healing
[0178] Example 12 indicates P4 D10 conjugate effect on healing
fractured bone after 4 weeks of various concentrations application
(1 nmol/day and 10 nmol/day, referred as 1.times. and 10.times.
respectively). The healing was reflected as BV/TV in FIG. 21 in a
dose dependent manner and bone volume in FIG. 22.
Example 13. MGF D10 Effect on Fracture Healing
[0179] Example 13 indicates mechano growth factor conjugate MGF D10
effect on healing fractured bone after 4 weeks of various
concentrations application (1 nmol/day and 10 nmol/day, referred as
1.times. and 10.times. respectively). The healing was reflected as
BV/TV in FIG. 23 in a dose dependent manner.
Example 14. TP508 D10 Effect on Fracture Healing
[0180] Example 14 indicates thrombin fragment TP508 conjugate TP508
D10 effect on healing fracture after 4 weeks of various
concentrations application (1 nmol/day and 10 nmol/day, referred as
1.times. and 10.times. respectively). The healing was reflected as
BV/TV in FIG. 24 in a dose dependent manner.
Example 15. VIP D10 Effect on Fracture Healing
[0181] Example 15 indicates vasoactive intestinal peptide conjugate
VIP D10 effect on healing fracture. Referring to FIGS. 25a and 25b,
healing was reflected as BV/TV (FIG. 25a) and TbTh (FIG. 25b) after
4 weeks of 1 nmol/day application (1.times.). Referring to FIGS.
26a, 26b, and 26c, in vivo fracture healing efficacy of
VIP_mp4_(D)E10 conjugate on Swiss Webster fracture-bearing mice
(n=5) after 3 weeks was reflected as BV/TV, Max Load, and Work to
Fracture respectively. BV/TV represents the bone volume divided by
total volume of the 100 thickest micro CT slices of the fracture
callus and is a measure of how dense the bone is at the site of
fracture repair. Max load represents the maximum force the healed
femur withstood before it refractured in a postmortem 4 point bend
analysis. Peak load is a measure of how strong the bone is at the
site of fracture repair. Work to fracture represents the total
amount of energy absorbed by the healed femur before it refractured
in a postmortem 4 point bend analysis. Work to fracture is a
measure of how strong the bone is at the site of fracture repair.
0.05.times. and 0.1.times. and 0.5.times. represent that a dose of
0.05 nmol, 0.1 nmol and 0.5 nmol of the conjugate was delivered
daily by subcutaneous injection. VIP_mp4_(D)E10 conjugate raises
bone density and bone strength at the fracture calluses three weeks
post fracture.
Example 16. D.sub.10-DOP Effect on Fracture Healing
[0182] Example 16 indicates sphinogosine-1-phosphate lyase
inhibitor conjugate DOP in vivo fracture healing efficacy after 3
weeks of 3 .mu.mol/kg every other day application (03Q), 10
.mu.mol/kg every other day application (1Q), three doses of 0.3
.mu.mol/kg in the third week application (003W3), three doses of
1.0 .mu.mol/kg in the third week application (01W3), three doses of
3 .mu.mol/kg in the third week application (03W3), and three doses
of 10 .mu.mol/kg in the third week application (1W3). The in vivo
fracture healing efficacy of D.sub.10-DOP conjugate on
fracture-bearing mice was reflected as BV/TV in FIG. 39.
D.sub.10-DOP conjugate raises bone density at the fracture calluses
three weeks post fracture. The conjugate remains active with
various dosing schedules.
Example 17. Ozanimod In Vitro Effect on Pre-Osteoblastic Cell Line
MC3T3-E1
[0183] Example 17 indicates the in vitro efficacy of ozanimod on
pre-osteoblastic cell line MC3T30E1. Specifically, example 17 shows
a boost in alkaline phosphatase (ALP) activity of pre-osteoblastic
cell line MC3T3-E1 following exposure to ozanimod of various
concentrations in the culture media for 7 days. Upregulated ALP
activity indicates promoted osteoblast differentiation. Referring
to FIG. 40, the ALP activity in mOD/min/ug protein is shown at 0.1
nM, 0.2 nM, 0.5 nM, 1 nM, and 5 nM concentrations of ozanimod and
dimethyl sulfoxide (DMSO) alone.
Example 18. D.sub.10-Ozanimod Effect on Fracture Healing
[0184] Example 18 indicates S1PR1 agonist conjugate
D.sub.10-ozanimod effect on healing fracture after 3 week of 0.01
.mu.mol/kg every day application (0.001.times.), 0.03 .mu.mol/kg
every day application (0.003.times.), 0.1 .mu.mol/kg every day
application (0.01.times.), 0.3 .mu.mol/kg every day application
(0.3.times.), and 1 .mu.mol/kg every day application (0.1.times.).
The in vivo fracture healing efficacy of D.sub.10-ozanimod
conjugate on fracture-bearing mice is reflected as BV/TV in FIG.
41. Daily dosages of D.sub.10-ozanimod conjugate raises bone
density at the fracture calluses three weeks post fracture. The
conjugate is effective over a wide dosage range.
Example 19. PACAP-(D)E.sub.10 Effect on Fracture Healing
[0185] Example 19 indicates PACAP-(D)E.sub.10 conjugate effect on
healing fracture after 3 weeks of 0.1 nmol per day application
(0.1.times.), 1 nmol per day application (1.times.), and 10 nmol
per day application (10.times.) delivered by subcutaneous
injection. The in vivo fracture healing efficacy of
PACAP-(D)E.sub.10 conjugate on Swiss Webster fracture-bearing mice
(n=5) after 3 weeks is reflected as BV/TV in FIG. 42, as Max Load
(Newtons) in FIG. 43, and Stiffness (N/mm) in FIG. 44.
PACAP-(D)E.sub.10 raises bone density, improves bone strength, and
improves bone stiffness at the fracture calluses three weeks post
fracture.
Example 20. Amylin(1-8)-D10 Effect on Fracture Healing
[0186] Example 20 indicates Amylin(1-8)-D.sub.10 effect on healing
fracture after 3 weeks of 1 nmol per day application (1.times.), 10
nmol per day application (10.times.), and 100 nmol per day
application (100.times.) delivered by subcutaneous injection. The
in vivo fracture healing efficacy of Amylin (1-8)-D.sub.10 on Swiss
Webster fracture-bearing mice (n=5) after 3 weeks is reflected as
BV/TV in FIG. 46, as Max Load (Newtons) in FIG. 47, and as Work to
Fracture (mJ) in FIG. 48. Amylin(1-8)-D.sub.10 conjugate raises
bone density, and improves bone strength at the fracture calluses
three weeks post fracture.
Example 21. CGRP (D)E.sub.10 Effect on Fracture Healing
[0187] Example 21 indicates CGRP (D)E.sub.10 conjugate effect on
healing fracture after 3 weeks of 0.1 nmol per day application
(0.1.times.), 1 nmol per day application (1.times.), and 10 nmol
per day application (10.times.) delivered by subcutaneous
injection. The in vivo fracture healing efficacy of CGRP
(D)E.sub.10 conjugate on Swiss Webster fracture-bearing mice (n=5)
after 3 weeks is reflected as BV/TV in FIG. 50, as Bone Volume (BV)
in FIG. 51, as Max Load (Newtons) in FIG. 52, and as Work to
Fracture (mJ) in FIG. 53. CGRP (D)E.sub.10 conjugate raises bone
density, stimulates more bone to be generated, and raises bone
strength at the fracture calluses three weeks post fracture.
Sequence CWU 1
1
22125PRTArtificial SequenceBFP D10 1Asp Asp Asp Asp Asp Asp Asp Asp
Asp Asp Gly Gln Gly Phe Ser Tyr1 5 10 15Pro Tyr Lys Ala Val Phe Ser
Thr Gln 20 25224PRTArtificial SequenceOGP D10 2Asp Asp Asp Asp Asp
Asp Asp Asp Asp Asp Ala Leu Lys Arg Gln Gly1 5 10 15Arg Thr Leu Tyr
Gly Phe Gly Gly 20327PRTArtificial SequencePreptin D10 3His Asp Val
Ser Thr Ser Gln Ala Val Leu Pro Asp Asp Phe Pro Arg1 5 10 15Tyr Asp
Asp Asp Asp Asp Asp Asp Asp Asp Asp 20 25421PRTArtificial
Sequencesubstance P 4 mini PEG D10 withMISC_FEATURE(10)..(11)4 mini
PEG linker 4Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Arg Pro Lys Pro
Gln Gln1 5 10 15Phe Phe Gly Leu Met 20538PRTArtificial
SequenceGhrelin D10 with Ser-3 replacementMISC_FEATURE(3)..(3)Ser-3
modified with diaminopropionic acid 5His Gly Ser Phe Leu Ser Pro
Glu His Gln Lys Ala Gln Gln Arg Lys1 5 10 15Glu Ser Lys Lys Pro Pro
Ala Lys Leu Gln Pro Arg Asp Asp Asp Asp 20 25 30Asp Asp Asp Asp Asp
Asp 35633PRTArtificial SequenceBMP9-D10MOD_RES(23)..(24)4 MINI PEG
LINKER 6Cys Gly Gly Lys Val Gly Lys Ala Cys Cys Val Pro Thr Lys Leu
Ser1 5 10 15Pro Ile Ser Val Leu Tyr Lys Asp Asp Asp Asp Asp Asp Asp
Asp Asp 20 25 30Asp733PRTArtificial SequenceCNP
D10DISULFID(17)..(33) 7His Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp
Gly Leu Ser Lys Gly1 5 10 15Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly
Ser Met Ser Gly Leu Gly 20 25 30Cys839PRTArtificial
SequenceVasoactive intestinal peptide with D10 (VIP D10) 8His His
Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys1 5 10 15Gln
Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn Asp Asp Asp 20 25
30Asp Asp Asp Asp Asp Asp Asp 35939PRTArtificial SequenceCBM D10
9His Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Gly Leu Arg Ser Lys1 5
10 15Ser Lys Lys Phe Arg Arg Pro Asp Ile Gln Tyr Pro Asp Ala Thr
Asp 20 25 30Glu Asp Ile Thr Ser His Met 351031PRTArtificial
SequenceP4 D10-a BMP2 fragment 10His Lys Ile Pro Lys Ala Ser Ser
Val Pro Thr Glu Leu Ser Ala Ile1 5 10 15Ser Thr Leu Tyr Leu Asp Asp
Asp Asp Asp Asp Asp Asp Asp Asp 20 25 301134PRTArtificial
SequenceMechano-growth factor (MGF) D10, an IGF-I fragment 11Asp
Asp Asp Asp Asp Asp Asp Asp Asp Asp Tyr Gln Pro Pro Ser Thr1 5 10
15Asn Lys Asn Thr Lys Ser Gln Arg Arg Lys Gly Ser Thr Phe Glu Glu
20 25 30His Lys1233PRTArtificial SequenceTP 508_D10 12Asp Asp Asp
Asp Asp Asp Asp Asp Asp Asp Ala Gly Tyr Lys Pro Asp1 5 10 15Glu Gly
Lys Arg Gly Asp Ala Cys Glu Gly Asp Ser Gly Gly Pro Phe 20 25
30Val1325PRTArtificial SequenceODP-D10MISC_FEATURE(10)..(11)4 mini
PEG linker 13Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Val Asp
Val Pro Asp1 5 10 15Gly Arg Gly Asp Ser Leu Ala Tyr Gly 20
251431PRTArtificial SequenceBMP9MISC_FEATURE(21)..(22) 14Gly Gly
Lys Val Gly Lys Ala Cys Cys Val Pro Thr Lys Leu Ser Pro1 5 10 15Ile
Ser Val Leu Tyr Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp 20 25
301535PRTArtificial SequenceGhrelin D10 15Phe Leu Ser Pro Glu His
Gln Lys Ala Gln Gln Arg Lys Glu Ser Lys1 5 10 15Lys Pro Pro Ala Lys
Leu Gln Pro Arg Asp Asp Asp Asp Asp Asp Asp 20 25 30Asp Asp Asp
351630PRTArtificial SequenceCNP-D10.MISC_FEATURE(15)..(16) 16Asp
Asp Asp Asp Asp Asp Asp Asp Asp Asp Gly Leu Ser Lys Gly Phe1 5 10
15Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly 20 25
301739PRTArtificial SequenceVIP D10 17His His Ser Asp Ala Val Phe
Thr Asp Asn Tyr Thr Arg Leu Thr Lys1 5 10 15Gln Met Ala Val Lys Lys
Tyr Leu Asn Ser Ile Leu Asn Asp Asp Asp 20 25 30Asp Asp Asp Asp Asp
Asp Asp 351811PRTArtificial Sequence4 mini PEG D10 18His Asp Asp
Asp Asp Asp Asp Asp Asp Asp Asp1 5 101926PRTArtificial
SequenceODPD10MISC_FEATURE(4)..(5)MISC_FEATURE(16)..(17) 19His Ala
Ile Ser Leu Tyr Leu Asp Glu Asn Glu Lys Val Val Leu Lys1 5 10 15Glu
Glu Glu Glu Glu Glu Glu Glu Glu Glu 20 252016PRTArtificial
SequencePACAP-(D)E10MISC_FEATURE(1)..(2)MISC_FEATURE(5)..(6)MISC_FEATURE(-
6)..(7) 20Lys Asn Thr Ala Thr Ala Asp Asp Asp Asp Asp Asp Asp Asp
Asp Asp1 5 10 152146PRTArtificial SequenceAmylin
1-8MISC_FEATURE(2)..(3)MISC_FEATURE(6)..(7)MISC_FEATURE(36)..(37)
21His Ser Asn Thr Ala Thr Val Thr His Arg Leu Ala Gly Leu Leu Ser1
5 10 15Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val
Gly 20 25 30Ser Glu Ala Phe Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu
35 40 452249PRTArtificial SequenceCGRP-E10 22His His Ser Asp Gly
Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys1 5 10 15Gln Met Ala Val
Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr 20 25 30Lys Gln Arg
Val Lys Asn Lys Glu Glu Glu Glu Glu Glu Glu Glu Glu 35 40 45Glu
* * * * *